Literature DB >> 25503656

Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .

Sahmin Lee1, Chang-Hwan Yoon, Il-Young Oh, Jung-Won Suh, Young-Seok Cho, Goo-Yeong Cho, In-Ho Chae, Dong-Ju Choi, Tae-Jin Youn.   

Abstract

The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described.A total of 210 consecutive patients with DES restenosis were enrolled from 2003 to 2012. We analyzed 217 restenotic lesions after DES implantation, and compared the morphologic characteristics of the 2nd generation DES restenosis to those of restenosis with 2 first generation DES, sirolimus-(SES) and paclitaxel-eluting stent (PES).Baseline characteristics were comparable between the different stent groups. The incidence of focal restenosis was significantly lower for PES than the other stents (49.5% versus 87.0%, 76.2%, and 82.1% for PES versus SES, EES, and ZES, respectively, P < 0.001). When considering the pattern of restenosis solely within the stent margins, a further clear distinction between PES and other stents was observed (40.0% versus 92.9%, 88.9%, and 81.2% in PES versus SES, EES, and ZES, respectively, P < 0.001). There were no significant differences in restenosis patterns among SES, EES, and ZES. In multivariate analysis, PES implantation, hypertension, and age were associated with non-focal type of restenosis after DES implantation. After the introduction of EES and ZES into routine clinical practice in 2008, focal restenosis significantly increased from 63.9% to 76.7% and diffuse restenosis significantly decreased from 26.4% to 11.0% (P = 0.045).Focal restenosis was the most common pattern of restenosis in the new generation DES and the incidence of diffuse restenosis significantly decreased with the introduction of the 2nd generation DES.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25503656     DOI: 10.1536/ihj.14-072

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  2 in total

1.  Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.

Authors:  Naoto Tama; Hiroyasu Uzui; Yuki Horita; Masanobu Namura; Hiroshi Tada
Journal:  Heart Vessels       Date:  2017-07-07       Impact factor: 2.037

2.  Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.

Authors:  Hyung Joon Joo; Han Saem Jeong; Hyungdon Kook; Seung Hun Lee; Jae Hyoung Park; Soon Jun Hong; Cheol Woong Yu; Do-Sum Lim
Journal:  BMC Cardiovasc Disord       Date:  2018-06-11       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.